This dataset contains complete product information for all approved, marketed, canceled and dormant products for human, veterinary, disinfectant and radiopharmaceutical use in the Canadian Drug Product Database (DPD) as of September 1, 2017. Before drug products are authorized for sale in Canada, Health Canada reviews them to assess the safety, efficacy, and quality. Drug products include prescription and non-prescription pharmaceuticals, disinfectants and sanitizers with disinfectant claims.

The Canadian Drug Product Database (DPD) contains product specific information on drugs approved for use in Canada, and includes human pharmaceutical and biological drugs, veterinary drugs and disinfectant products. This information includes 'brand name', 'route of administration' and a Canadian 'Drug Identification Number' (DIN).

This dataset contains complete active ingredient information for all approved, marketed, canceled and dormant products for human, veterinary, disinfectant and radiopharmaceutical use in the Canadian Drug Product Database (DPD) as of September 1, 2017. Before drug products are authorized for sale, Health Canada reviews them to assess their safety, efficacy, and quality. Drug products include prescription and non-prescription pharmaceuticals, disinfectants and sanitizers with disinfectant claims.

This dataset contains the Applications part to build the Drugs@FDA database. Drugs at FDA is a database of FDA Approved Drug Products available on the FDA official website. It provides information of drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

The Table below, updated weekly, contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database. Each file on this table represents a snapshot of data in the system and is not updated by subsequent changes. Once the covered outpatient drugs in each of these files appear in the quarterly MDRP database, the file will be removed from this table. States can utilize these files to identify newly reported covered outpatient drugs.

Study design We conducted a cross-sectional study to quantify the number and describe the characteristics of prescription drugs on the Canadian market as of August 23, 2022 with a patient support program defined as services (including but not limited to financial assistance) offered to patients prescribed a specific drug and initiated and funded by the manufacturer. We then conducted a structured content analysis of web-based sources to understand the types and range of supports provided to patients through these programs. We chose to rely exclusively on publicly available data sources to both identify and describe manufacturer-sponsored patient support programs as these are sources currently available to patients when making program enrolment decisions and policymakers seeking to understand the extent and impact of this model of care. Sampling frame Because the European Medicines Association defines a patient support program as services for a specific drug offered by the company holding the marketing authorization, we first sought to identify all drug companies with currently marketed, prescription products in Canada. Between June 27, 2022 and August 23, 2022, two investigators independently extracted the names of all member companies listed on the websites of the three main trade associations for the Canadian pharmaceutical industry (Innovative Medicines Canada, representing the research-based pharmaceutical industry; BIOTECanada, representing the biotechnology industry; and the Canadian Generic Pharmaceutical Association, representing generic drug manufacturers). Because trade association membership is voluntary, we supplemented this list with non-member drug manufacturers identified in previous research. Using the Health Canada Drug Product Database,two investigators independently screened the list of companies and included those with marketed, prescription products and excluded companies that were not drug manufacturers (e.g., law firms) or without currently marketed prescription drugs (e.g., products under development). Discrepancies were resolved through discussion or adjudication by a third author. Sample and variables Using the Health Canada Drug Product Database, one investigator searched each identified drug manufacturer and extracted the product and active ingredient name(s) for all marketed, prescription drugs. We counted a single “drug” as all dosages, formulations, or routes of administration with the same active ingredients and manufacturer since industry patient support programs are brand-specific and do not typically differentiate among these factors. We selected variables that reflect known characteristics of drugs that may be associated with having a patient support program, and for which data were publicly available. One investigator also extracted Schedule D (biologic) status, route(s) of administration, and Level 1 Anatomical Therapeutic Chemical (ATC) code from the Drug Product Database and Product Monograph and identified whether the drug had Orphan Drug Status using the searchable United States database. On the basis of type of Health Canada regulatory review (i.e. innovator or subsequent entry), clinical expertise, and knowledge about the manufacturer, two investigators independently identified the brand status of each drug as brand (i.e. “innovator” products first to market); branded generic (i.e. “subsequent entry” products which are bioequivalent or biosimilar to an existing product on the market, but given a proprietary name); or generic (i.e. “subsequent entry” products which are bioequivalent to an existing product on the market). We classified biosimilars as branded generics. We resolved discrepancies through discussion, and/or adjudication by a third author. Identifying patient support programs and their characteristics Our primary outcome was whether a sampled drug had an associated manufacturer-sponsored patient support program. We defined a patient support program as any combination of services or resources related to medication access, administration, adherence, education, storage, or disposal for patients prescribed a specific product and initiated, sponsored and/or operated by the company holding the product’s marketing authorization. We distinguished patient support programs from “patient assistance programs,” excluding programs that exclusively provided financial assistance (e.g., coupons, co-pay coverage, etc.); expanded or compassionate access programs; risk management programs outlined in the Product Monograph (initiated by the regulator rather than the manufacturer); and programs delivered solely for a clinical study. Two investigators independently performed structured searches on Google (“[company name] AND patient support program AND Canada” and “[drug brand name] AND patient support program AND Canada”) to identify industry sponsored patient support programs in Canada and resolving discrepancies through discussion. Using Zotero, a reference management...

According to 21 CFR 210.3(b)(8), an inactive ingredient is any component of a drug product other than the active ingredient. Only inactive ingredients in the final dosage forms of drug products are in this database.

This dataset contains the Application Submission Property Type part to build the Drugs@FDA database. Drugs at FDA is a database of FDA Approved Drug Products available on the FDA official website. It provides information of drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

The Canadian Clinical Drug Dataset is a drug terminology and coding system designed to allow the interchange of standardized drug and medical device information between diverse digital health systems. Some use cases include electronic prescribing, electronic medical records, medication reconciliation and analytics. It also provides for the classification and identification of defined groups of medications (called special groupings), such as narcotic and controlled drugs. It has the capacity to be used by knowledge-based vendors, clinicians, researchers, statistical users, government agencies, healthcare organisations and consumers. The data source for the CCDD is the Drug Product Database (DPD) which contains information on drugs approved by Health Canada. However, the data is modeled differently following the CCDD Editorial Guidelines which take into consideration international terminology standards. For example, DPD uses the dosage form, “tablet (delayed-release)”, whereas CCDD uses the equivalent term “gastro-resistant tablet.” The Canadian Clinical Drug Data Set does not replace the Health Canada Drug Product Database (DPD) but is published in addition to it. The scope of health products included in CCDD is limited to those classified as human in DPD (veterinary, radiopharmaceutical and disinfectant products are out of scope). Some exclusions apply within the human class but are subject to periodic review: For a full list of exclusions, please see the Scope section in the CCDD Editorial Guidelines. In addition, a limited number of medical devices that are commonly prescribed and dispensed at a community pharmacy are included. This data set was developed in collaboration with Canada Health Infoway and is also available in their Terminology Gateway at https://tgateway.infoway-inforoute.ca/ccdd.html (Free login required)

This medical dataset contains the Application Submission part to build the Drugs@FDA database from the Food and Drug Administration (FDA) Approved Drug Products available on their official website. It provides information on drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status, and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

The National Drug Code (NDC) Products of Unfinished Drugs dataset contains NDC product listing data submitted for all unfinished drugs. Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily.

A database of ingredients in brand-name household products linked to health information from Material Safety Data Sheets (MSDS) provided by manufacturers. The database is designed to help answer the following typical questions: *What are the chemical ingredients and their percentage in specific brands? *Which products contain specific chemical ingredients? *Who manufactures a specific brand? How do I contact this manufacturer? *What are the acute and chronic effects of chemical ingredients in a specific brand? *What other information is available about chemicals in the toxicology-related databases of the National Library of Medicine? NLM and its Contractor (the Database Providers) do not test products nor investigate to determine if this information is complete or accurate.

The Inactive Ingredient Database provides information on inactive ingredients present in Food and Drug Administration (FDA) approved drug products. This information can be used by industry as an aid in developing drug products.

Information about FDA-approved brand name and generic prescription and over-the-counter human drugs and biological therapeutic products. Drugs@FDA includes most of the drug products approved since 1939. The majority of patient information, labels, approval letters, reviews, and other information are available for drug products approved since 1998.

The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.

Health Canada's Clinical Trials Database is a listing of information about phase I, II and III clinical trials in patients. The database is managed by Health Canada and provides a source of information about Canadian clinical trials involving human pharmaceutical and biological drugs. Additional information on Health Canada’s CTD is available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/health-canada-clinical-trials-database/frequently-asked-questions.html

This statistic depicts a list of selected FDA-approved prescription drugs, which were later pulled from the U.S. market. The longest running FDA-approved drug which was later recalled from the market was Darvon & Darvocet, between 1955 and 2010, which stayed in the market for 55 years. The reason for the recall was serious toxicity to the heart: between 1981 and 1999 there were over 2,110 deaths reported connected to that drug. According to the Food and Drug Adminitration (FDA), a "drug is removed from the market when its risks outweigh its benefits. A drug is usually taken off the market because of safety issues with the drug that cannot be corrected, such as when it is discovered that the drug can cause serious side effects that were not known at the time of approval."

This data package contains information about the drugs and chemicals that contribute to certain symptoms or diseases. It also includes adverse drug reactions that are associated with the product and substance with MedDRA Preferred Term (PT), PT codes and System Organ Class (SOC) codes.

Natural products and semi-synthetic compounds continue to be a significant source of drug candidates for a broad range of diseases, including the current pandemic caused by COVID-19. Besides being attractive sources of bioactive compounds for further development or optimization, natural products are excellent candidates of unique substructures for fragment-based drug discovery inspired on natural products. To this end, fragment libraries are required that can be incorporated into automated drug design pipelines. However, it is still scarce to have public fragment libraries based on extensive collections of natural products. Herein we report the generation and analysis of a fragment library of natural products derived from a database with more than 400,000 compounds. We also report fragment libraries of food chemical databases and other compound data sets of interest in drug discovery, including compound libraries relevant for COVID-19 drug discovery. The fragment libraries were characterized in terms of contents and diversity.Sopporting information contains: COCONUT_COMPOUNDS.csv, FooDB_COMPOUNDS.csv, DCM_COMPOUNDS.csv, CAS_COMPOUNDS.csv, 3CLP_COMPOUNDS.csv. All datasets contain the curated structures and the following information: identicator number (ID), simplified molecular input line entry system (Smiles), Average Molecular Weight (AMW), number of carbons, oxygens, nitrogens, heavy atoms, aliphatic rings, aromatic rings, heterocycles, bridgehead atoms, fraction of sp3 carbon atoms and chiral carbons, and a list of fragments generated from each compound. FRAGMENTS_COCONUT.csv, FRAGMENTS_FooDB.csv, FRAGMENTS_DCM.csv, FRAGMENTS_CAS.csv, FRAGMENTS_3CLP.csv. All libraries contain structures generated (Fragments) from each compound library (Dataset) and the following information: number of compounds that contain that fragment in a dataset (Count) and fraction of them (Proportion), average Molecular Weight (AMW), number of carbons, oxygens, nitrogens, heavy atoms, aliphatic rings, aromatic rings, heterocycles, bridgehead atoms, fraction of sp3 carbon atoms and chiral carbons.

Additional file 1. Chemical compounds of the Natural Compound Databases (NCDBs).